- Fund Type: Open-End Fund
- Objective: Government/Corporate
- Asset Class: Debt
- Geographic Focus: Israel
Analyst 0A Government Bonds With No Equity
+ Add to WatchlistAN0AG20:IT
116.48 ILs 0.46 0.40%As of 00:59:30 ET on 05/16/2013.
Snapshot for Analyst 0A Government Bonds With No Equity (AN0AG20)
| Year To Date: | +2.62% | 3-Month: | +3.08% | 3-Year: | +4.83% | 52-Week Range: | 107.20 - 116.48 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +1.74% | 1-Year: | +8.75% | 5-Year: | - | Beta vs TA-100: | 0.37 |
Fund Profile & Information for AN0AG20
Analyst 0A Government Bonds With No Equity is an open-end fund incorporated in Israel.
| Inception Date: | 12-27-2009 | Telephone: | 972-3-7147147 Tel |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | - | ||
Fundamentals for AN0AG20
| NAV | (on 2013-05-16) 116.48 |
|---|---|
| Assets (M) | (on 2013-04-30) 120.90 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for AN0AG20
No dividends reported
Fees & Expenses for AN0AG20
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | - |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for AN0AG20
Filing Date: 01/31/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| GALIL 4 07/30/21 | 9,750 | 15,527,850 | 14.149% |
| ILCPI 1 ½ 06/30/14 | 12,700 | 14,665,960 | 13.364% |
| MAKAM 0 04/03/13 | 14,500 | 14,457,950 | 13.174% |
| ILGOV 5 ½ 01/31/22 | 10,000 | 11,229,000 | 10.232% |
| ILCPI 3 ½ 04/30/18 | 8,000 | 10,908,800 | 9.940% |
| ILGOV 5 01/31/20 | 7,000 | 7,667,100 | 6.986% |
| ILGOV 6 02/28/19 | 6,300 | 7,626,149 | 6.949% |
| ILGOV 3 ½ 09/30/13 | 7,000 | 7,163,800 | 6.528% |
| ILGOV 5 03/31/13 | 3,000 | 3,142,500 | 2.863% |
| ILCPI 3 10/31/19 | 2,500 | 3,100,750 | 2.825% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page